IN8bio, Inc

Contributing Author

Recent Articles by IN8bio, Inc

Jan-12	IN8bio Presents Updated Phase I/II Data Demonstrating Meaningful and Durable Survival Improvements in Newly Diagnosed Glioblastoma INAB GlobeNewswire
Dec-19	IN8bio Announces Pricing of Private Placement of up to $40.2 Million to Advance Novel Gamma-Delta T Cell Engager INAB GlobeNewswire
Nov-06	IN8bio Reports Third Quarter 2025 Financial Results and Recent Business Highlights INAB GlobeNewswire
Oct-29	IN8bio Expands INB-100 Phase 1 Clinical Trial with Addition of The Ohio State University as New Site INAB GlobeNewswire
Oct-27	IN8bio Presents T cell Engager Data Demonstrating Deep B Cell Depletion for Autoimmune Indications INAB GlobeNewswire
Aug-07	IN8bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights INAB GlobeNewswire
Jun-09	IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma Trial INAB GlobeNewswire
Jun-02	IN8bio Presents Positive Phase 1 Data of INB-200 in Newly Diagnosed GBM Demonstrating Prolonged Progression-Free Survival INAB GlobeNewswire
May-14	IN8bio Presents Preclinical Data Highlighting Potential of INB-619 T Cell Engager (TCE) for Autoimmune Disease at ASGCT 2025 INAB GlobeNewswire
May-12	IN8bio Presents Data at ISCT 2025 Demonstrating Proprietary γδ T cell Manufacturing Generates Consistent and Robust Clinical Products INAB GlobeNewswire
May-07	IN8bio Reports First Quarter 2025 Financial Results and Recent Business Highlights INAB GlobeNewswire